Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.

3 weeks ago 23

Lee Samaha, The Motley Fool

Mon, July 13, 2026 astatine 6:35 AM CDT 5 min read

Multi-cancer aboriginal detection (MCED) trial institution Grail (NASDAQ: GRAL) has immoderate precise high-profile backers. None different than Amazon laminitis Jeff Bezos and Microsoft co-founder Bill Gates were aboriginal signifier investors successful the company, which was past bought by Illumina successful 2021 and spun disconnected successful 2024. Although the banal has intelligibly attracted a batch of attention, it besides shocked investors with atrocious quality earlier this year, sending it crashing 50%. Still, it's made a comeback successful caller months, and it's clip for investors to inquire whether it's a bargain now.

Grail and its multi-cancer aboriginal detection test, Galleri

To reply the question, it's important to recognize wherefore the banal crashed and wherefore it's already recovered overmuch of its losses. The crushed for the clang successful February came down to the mixed top-line results of the landmark three-year proceedings of its MCED test, Galleri, with the U.K.'s National Health Service (NHS).

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

The thought down an MCED trial is that it volition summation aboriginal signifier (stage I and II) crab detection truthful the illness tin beryllium treated earlier it reaches the much pervasive, painful, later-stage cancers (stages III and IV), which are harder and much costly to treat. As such, the NHS-Galleri trial should show a meaningful simplification successful late-stage crab detection successful the trial radical compared with the power group, arsenic cancers should beryllium detected earlier successful the trial group. Unfortunately, that's not what the top-line results said: "The superior endpoint of statistically important Stage III-IV simplification was not observed. However, determination was a favorable inclination toward less Stage III-IV cancers successful a pre-specified radical of 12 deadly cancers."

The archetypal condemnation unsocial was capable to nonstop the banal down much than 50% connected the time of the NHS-Galleri trial results release, portion increasing optimism astir the 2nd condemnation led to a partial betterment successful the banal successful caller months.

What truly matters to Grail

The Galleri trial is already disposable arsenic a Laboratory Developed Test (LDT) and tin beryllium purchased retired of pocket, arsenic it lacks afloat Food and Drug Administration (FDA) support and isn't wide covered by commercialized wellness insurers' plans oregon Medicare. Although Galleri income are rising connected this basis, the existent catalyst for Galleri and Grail banal volition travel from a operation of FDA support (Grail has submitted an application) and, successful turn, substantive adoption by aesculapian insurers, including Medicare.

Read Entire Article